Evotec SE (NASDAQ:EVO - Get Free Report) shares dropped 6.8% during trading on Tuesday . The stock traded as low as $4.39 and last traded at $4.41. Approximately 35,717 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 131,540 shares. The stock had previously closed at $4.73.
Analyst Ratings Changes
A number of analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Evotec has an average rating of "Hold" and an average price target of $5.93.
Check Out Our Latest Analysis on Evotec
Evotec Stock Up 5.8%
The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The stock's 50-day simple moving average is $3.78 and its two-hundred day simple moving average is $4.17.
Institutional Investors Weigh In On Evotec
A number of large investors have recently modified their holdings of the business. ABC Arbitrage SA purchased a new stake in shares of Evotec during the first quarter worth $260,000. DCF Advisers LLC grew its holdings in shares of Evotec by 227.0% during the first quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after buying an additional 521,708 shares in the last quarter. CSS LLC IL purchased a new stake in shares of Evotec during the fourth quarter worth $50,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the fourth quarter worth $166,000. Finally, Bank of America Corp DE grew its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
